Last Update 04 Mar 26
Fair value Increased 22%DAR: Fair Outlook Balances Q4 EBITDA Expectations And Collagen Joint Venture Execution
Analysts have raised their fair value estimate for Darling Ingredients from $45.00 to $55.00. They cited refreshed models that reflect updated assumptions on revenue growth, profit margins, and future P/E ratios, following a wave of recent price target increases across the Street.
Analyst Commentary
Recent Street research on Darling Ingredients has centered on recalibrated price targets, updated ratings, and refreshed earnings assumptions, especially around Q4 performance and profitability. Several firms have published new target prices that cluster in a relatively tight band, which helps you frame where current analyst expectations sit on valuation and potential execution.
Some research has referenced Q4 results and EBITDA expectations, including a preview that cited Q4 EBITDA of $284m ex LCM and a comparison to consensus estimates. Other reports have focused more on adjusting target prices by single or double digit dollar amounts, reflecting revised views on earnings power and the appropriate P/E multiple to apply.
For you as an investor, the key takeaway is that analysts are reacting to the same set of information, but are expressing different levels of confidence around how consistently Darling can deliver on revenue growth, margins, and cash generation over time. That mix of enthusiasm and restraint shows up clearly in the more cautious commentary.
Bearish Takeaways
- Bearish analysts are flagging the risk that current valuation already bakes in optimistic assumptions on revenue growth and margins, which could limit upside if Q4 and subsequent quarters come in closer to existing consensus rather than materially stronger.
- Several price target adjustments, even when higher in dollar terms, point to concerns that execution across segments like Feed and DGD may be uneven, especially if the company faces cost pressures or slower volume trends that constrain EBITDA progression.
- Cautious research notes highlight that multiple target changes in quick succession can signal uncertainty around the durability of earnings drivers, with some analysts questioning how sustainable any Q4 strength might be over a longer horizon.
- Where price targets have been lifted by relatively modest amounts, bearish analysts are effectively signaling that upside, in their view, is more limited from current levels and remains sensitive to any disappointment on reported results or guidance.
What's in the News
- Darling Ingredients signed a definitive agreement with Tessenderlo Group to combine their collagen and gelatin segments into a new company, with no cash or initial investment required from either party (Key Developments).
- The combined business will bring together Darling's Rousselot unit and Tessenderlo's PB Leiner unit, creating a collagen focused health, wellness and nutrition products company aimed at global collagen demand (Key Developments).
- Darling Ingredients is set to hold an 85% ownership stake in the new company, with Tessenderlo Group holding 15% (Key Developments).
- The combined entity is initially expected to have about US$1.5b in annual revenue and around 200,000 metric tons of gelatin and collagen capacity across 22 facilities in South America, North America, Europe and Asia (Key Developments).
- The transaction is subject to regulatory approvals and is expected to close in 2026, with management highlighting potential synergies and product development opportunities in the Nextida portfolio (Key Developments).
Valuation Changes
- Fair Value: Raised from $45.00 to $55.00, representing a meaningful step up in the reference valuation level.
- Discount Rate: Adjusted slightly higher from 6.96% to 6.98%, indicating a small change in the required return used in the model.
- Revenue Growth: Updated assumption increased from 3.80% to 4.31%, indicating a somewhat stronger top line growth outlook in the model.
- Net Profit Margin: Revised from 9.63% to 14.21%, marking a sizable uplift in expected profitability on future $ revenue.
- Future P/E: Reduced from 13.65x to 10.75x, indicating a lower multiple applied to forward earnings despite the higher fair value estimate.
Key Takeaways
- Regulatory uncertainty and compliance costs threaten profit margins and growth, despite favorable trends supporting renewable fuels and waste upcycling.
- Diversification into new products and global expansion face risks from market acceptance, competition for inputs, and execution challenges, which could limit long-term gains.
- Exposure to regulatory shifts, market disruption, and rising competition threatens margin stability, growth prospects, and future shareholder returns, especially given elevated leverage and muted core segment performance.
Catalysts
About Darling Ingredients- Develops, produces, and sells natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally.
- Although regulatory trends in the U.S. and abroad are increasingly favoring the use of domestic feedstocks and incentivizing renewable fuel production, the company faces ongoing policy uncertainties such as delayed RIN compliance enforcement and unresolved small refinery exemptions, which are likely to create unpredictable margin pressure and hinder EBITDA growth in the near-to-medium term.
- While Darling Ingredients is well-positioned to benefit as governments accelerate mandates for biofuel blending and greenhouse gas reductions, there is a significant risk that further regulatory scrutiny on animal-based inputs, water use, and waste management will drive up compliance costs and erode net margins over the long run.
- Despite the company's drive to expand production of high-value, health-oriented products through its planned Nextida joint venture and ongoing scientific trials, the success of these products hinges on clinical outcomes and market acceptance, meaning the expected boost to revenues and gross margins from this diversification could be delayed or diminished if adoption rates fall short.
- While the push for a circular economy and global waste valorization initiatives supports rendering and upcycling business lines, increased competition for animal byproducts from emerging uses such as pet food and alternative proteins could lead to higher input costs and compressed gross margins, limiting the sustainability of margin expansion seen in recent quarters.
- Although capital discipline and refinancing have improved Darling's financial flexibility and reduced debt costs in the short run, overexpansion or integration missteps from international acquisitions, combined with market risks such as lower global demand for traditional animal-derived ingredients due to rising alternative proteins, may ultimately pressure long-term cash flow, asset utilization, and overall earnings growth.
Darling Ingredients Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- This narrative explores a more pessimistic perspective on Darling Ingredients compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Darling Ingredients's revenue will grow by 3.5% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 1.8% today to 8.2% in 3 years time.
- The bearish analysts expect earnings to reach $519.5 million (and earnings per share of $3.21) by about September 2028, up from $105.4 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 12.4x on those 2028 earnings, down from 47.0x today. This future PE is lower than the current PE for the US Food industry at 19.5x.
- Analysts expect the number of shares outstanding to decline by 0.54% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.
Darling Ingredients Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Darling Ingredients' long-term profitability remains highly exposed to regulatory changes, particularly shifts in renewable fuel mandates, RIN and LCFS structures, and subsidy support, which have already led to lower renewable diesel margins and could continue to impact segment earnings if government incentives are reduced or delayed.
- The company's core Feed and Food Segments showed flat or only modest growth in raw material volumes and revenues, indicating potential secular stagnation in traditional animal byproduct streams, which may limit top-line revenue growth if alternative proteins and plant-based substitutes gain further market share.
- Darling's heavy capital investment in renewable diesel (DGD) and specialty joint ventures increases execution risk, especially if integration issues, unforeseen market disruptions, or a prolonged downturn in global demand for animal byproducts occur, potentially resulting in lower ROIC and weaker net margins.
- Competitive and regulatory pressures in global markets, including tariffs, localization trends, and shifting consumer preferences towards sustainable, traceable, or non-animal-derived products, could shrink the company's export demand and lead to higher input costs, thereby compressing gross and operating margins over the long term.
- The company's high leverage, with total debt near $3.9 billion and a leverage ratio just above 3.3x, combined with mixed profitability trends (including a recent net loss year-to-date), imposes financial risk; ongoing capital discipline and any further margin compression could constrain future capacity for growth investments, dividends, or share buybacks, negatively impacting future earnings and shareholder returns.
Valuation
How have all the factors above been brought together to estimate a fair value?- The assumed bearish price target for Darling Ingredients is $34.0, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Darling Ingredients's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $34.0.
- In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $6.3 billion, earnings will come to $519.5 million, and it would be trading on a PE ratio of 12.4x, assuming you use a discount rate of 6.8%.
- Given the current share price of $31.3, the bearish analyst price target of $34.0 is 7.9% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Darling Ingredients?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.



